InsidersTradesSigma
Track the BIO share price and the full directors' dealings record of the company, a publicly traded company based in Australia. Shares trade on AU AU, under the authority of ASX. Market capitalisation: €67.3m. The latest transaction was reported on 25 June 2026 (Purchase). Among the most active insiders: Blair Vega Norfolk. All data is openly available.
Analysts rate BIO Strong Buy (bullish), based on 1 analysts. Average price target: A$0.75.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
3 of 3 declarations
BIO is a company listed on the XASX market, specializing in the biotechnology sector. It focuses on developing innovative health solutions.